Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
L Elizabeth Elizabeth BuddeSarit E AssoulineLaurie Helen SehnStephen J SchusterSung-Soo YoonDok Hyun YoonMatthew J MatasarFrancesc BoschWon Seog KimLoretta J NastoupilIan W FlinnMazyar ShadmanCatherine S DiefenbachCarol O'HearHuang HuangAntonia KwanChi-Chung LiEmily C PiccioneMichael C WeiShen YinNancy L BartlettPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Mosunetuzumab, administered with step-up dosing, has a manageable safety profile and induces durable complete responses in R/R B-NHL. The expansion stage of the study is ongoing at the dose level of 1/2/60/60/30 mg selected for further study.